The department, in consultation with the Center for Medical Cannabis Research created in Section 53H-4-206, shall:

1. (1) develop evidence-based guidance for treatment with medical cannabis based on the latest medical research that shall include:

   1. (a) for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis;
   2. (b) risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and
   3. (c) potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration;

2. (2) educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding:

   1. (a) the evidence-based guidance for treatment with medical cannabis described in Subsection (1)(a);
   2. (b) relevant warnings and safety information related to medical cannabis use; and
   3. (c) other topics related to medical cannabis use as determined by the department; and

3. (3) develop patient product information inserts for medical cannabis products:

   1. (a) in consultation with the cannabis processing facility that created the product; and
   2. (b) that do not contain proprietary information about the product.

Amended by Chapter 9, 2025 Special Session 1